On July 29, Boston Scientific declined 7.62% in regular trading, trading at approximately $43.31 per share, with turnover of $118 million. The stock reversed sharply from pre-market gains after the company's earnings call revealed disappointing forward guidance.

While Q2 adjusted EPS of $0.86 beat the consensus estimate of $0.83 and net sales of $5.44 billion exceeded the $5.36 billion expectation, management lowered full-year adjusted EPS guidance to $3.28-$3.32, below the Street consensus of $3.36. Full-year net sales growth was cut to 5.5%-6.5% from the prior 7%-8.5% projection. The core drag came from the Watchman heart closure device business, with management disclosing that H2 Watchman revenue is expected to decline mid-to-high single digits year-over-year, as physicians increasingly combine the procedure with other cardiac surgeries, reducing standalone procedure volumes. Q3 guidance of $0.80-$0.82 EPS also trailed the $0.84 analyst estimate. Separately, the company disclosed a global restructuring plan with $700-$800 million in charges, targeting approximately $500 million in annual cost savings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)